Annual report pursuant to Section 13 and 15(d)

Segment reporting (Tables)

v3.10.0.1
Segment reporting (Tables)
 12 Months Ended
Jul. 31, 2018
Segment Reporting [Abstract]  
Schedule of Segment Reporting Information, by Segment [Table Text Block] The following financial information represents the operating results of the reportable segments of the Company:

Year ended July 31, 2018   Clinical
Laboratory Services		     Life
Sciences Products		     Therapeutics     Other     Consolidated  
Revenues:                                        
Clinical laboratory services   $ 74,777       —       —       —     $ 74,777  
Product revenues     —     $ 29,224       —       —       29,224  
Royalty and license fee income     —       712       —       —       712  
Total revenues     74,777       29,936       —       —       104,713  
                                         
Operating costs and expenses:                                        
Cost of clinical laboratory services     46,008       —       —       —       46,008  
Cost of product revenues     —       14,377       —       —       14,377  
Research and development     —       2,305     $ 905       —       3,210  
Selling, general and administrative     24,656       11,627       —     $ 8,182       44,465  
Provision for uncollectible accounts receivable     3,700       (10 )     —       —       3,690  
Legal fee expense     67       58       —       5,002       5,127  
Total operating costs and expenses     74,431       28,357       905       13,184       116,877  
                                         
Operating income (loss)     346       1,579       (905 )     (13,184 )     (12,164 )
                                         
Other income (expense)                                        
Interest     (91 )     50       —       894       853  
Other     29       11       —       128       168  
Foreign exchange gain     —       (275 )     —       —       (275 )
Income (loss) before taxes   $ 284     $ 1,365     $ (905 )   $ (12,162 )   $ (11,418 )
                                         
Depreciation and amortization included above   $ 1,667     $ 1,387     $ —     $ 76     $ 3,130  
                                         
Share-based compensation included in above:                                        
Selling, general and administrative     125       79       —     $ 609       813  
Total   $ 125     $ 79     $ —     $ 609     $ 813  
                                         
Capital expenditures   $ 1,685     $ 203     $ —     $ —     $ 1,888  
Year ended July 31, 2017   Clinical
Laboratory Services		     Life
Sciences Products		     Therapeutics     Other     Consolidated  
Revenues:                                        
Clinical laboratory services   $ 77,407       —       —       —     $ 77,407  
Product revenues     —     $ 29,192       —       —       29,192  
Royalty and license fee income     —       1,205       —       —       1,205  
Total revenues     77,407       30,397       —       —       107,804  
                                         
Operating costs, expenses and legal settlements, net:                                        
Cost of clinical laboratory services     45,400       —       —       —       45,400  
Cost of product revenues     —       14,078       —       —       14,078  
Research and development     —       2,311     $ 617       —       2,928  
Selling, general and administrative     24,465       11,232       —     $ 8,395       44,092  
Provision for uncollectible accounts receivable     2,718       57       —       —       2,775  
Legal fee expense     146       79       —       1,454       1,679  
Total operating costs, expenses and legal settlements, net     72,729       27,757       617       9,767       110,952  
                                         
Operating income (loss)     4,678       2,640       (617 )     (9,767 )     (3,148 )
                                         
Other income (expense)                                        
Interest     (112 )     46       —       450       384  
Other     137       (60 )     —       48       125  
Foreign exchange gain     —       135       —       —       135  
Income (loss) before taxes   $ 4,703     $ 2,761     $ (617 )   $ (9,269 )   $ (2,504 )
                                         
Depreciation and amortization included above   $ 1,586     $ 1,913     $ —     $ 99     $ 3,598  
                                         
Share-based compensation included in above:                                        
Cost of clinical laboratory services   $ 6     $ —     $ —     $ —     $ 6  
Selling, general and administrative     111       74       —     $ 640       825  
Total   $ 117     $ 74     $ —     $ 640     $ 831  
                                         
Capital expenditures   $ 1,363     $ 390     $ —     $ —     $ 1,753  
Year ended July 31, 2016   Clinical
Laboratory
Services 		    Life
Sciences
Products 		    Therapeutics     Other     Consolidated  
Revenues:                                        
Clinical laboratory services   $           70,915       —       —       —     $ 70,915  
Product revenues     —     $ 30,337       —       —       30,337  
Royalty and license fee income     —       1,521       —       —       1,521  
Total revenues     70,915       31,858       —       —       102,773  
                                         
Operating costs, expenses and legal settlements, net:                                        
Cost of clinical laboratory services     42,859       —       —       —       42,859  
Cost of product revenues     —       14,331       —       —       14,331  
Research and development     —       2,720     $ 804       —       3,524  
Selling, general and administrative     22,882       11,761       —     $ 9,098       43,741  
Provision for uncollectible accounts receivable     2,375       (39 )     —       —       2,336  
Legal fee expense     134       11       —       6,239       6,384  
Legal settlements, net     1,500       (58,750 )     —       —       (57,250 )
Total operating costs, expenses and legal settlements, net     69,750       (29,966 )     804       15,337       55,925  
                                         
Operating (loss) income     1,165       61,824       (804 )     (15,337 )     46,848  
                                         
Other income (expense)                                        
Interest     (105 )     47       —       (78 )     (136 )
Other     10       38       —       74       122  
Foreign exchange gain     —       (474 )     —       —       (474 )
                                         
(Loss) income before income taxes   $ 1,070     $ 61,435     $ (804 )   $ (15,341 )   $ 46,360  
                                         
Depreciation and amortization included above   $ 1,676     $ 2,091     $ —     $ 73     $ 3,840  
                                         
Share-based compensation included in above:                                        
Cost of clinical laboratory services   $ 6     $ —     $ —     $ —     $ 6  
Selling, general and administrative     51       30       —     $ 438       519  
Total   $ 57     $ 30     $ —     $ 438     $ 525  
                                         
Capital expenditures   $ 1,216     $ 314     $ —     $ —     $ 1,530  
Schedule of Revenue from External Customers and Long-Lived Assets, by Geographical Areas [Table Text Block] Geographic financial information is as follows:

Net sales to unaffiliated customers:   2018     2017     2016  
United States   $ 95,388     $ 99,469     $ 94,016  
Switzerland     2,584       2,371       2,709  
United Kingdom     1,851       1,673       1,730  
Other international countries     4,890       4,291       4,318  
Total   $ 104,713     $ 107,804     $ 102,773  
                         
Long-lived assets at July 31,     2018       2017          
United States   $ 16,210     $ 17,241          
Switzerland     502       649          
United Kingdom     127       185          
Other international countries     135       173          
Total   $ 16,974     $ 18,248          
Schedule of Segment Revenue By Geographical [Table Text Block] The following is a summary of the Life Sciences Products segment revenues attributable to customers located in the United States and foreign countries:

    2018     2017     2016  
United States   $ 19,898     $ 22,062     $ 23,102  
Foreign countries     9,326       8,335       8,756  
    $ 29,224     $ 30,397     $ 31,858